| Organiser | European School of Urology |
|---|---|
| CME | 1 |
| Duration | Approx. 60 – 90 minutes |
The tumor microenvironment shapes the response to treatment. How can we manipulate that environment to optimize the effect of immunotherapy in urological cancers? Can drugs targeting the TGF-beta-signalling pathway help us improve the patient care? Are oncolytic viruses, both the ones that kill tumor cells and the ones that promote antitumour responses, ready to be implemented in the toolbox for treating cancers? How do we envision the use of next-generation immunotherapies in the clinical practice?